Second congressional drug price inquiry vows to compel deposition from CEOs

The US Senate Finance Committee, led by Chairman Charles Grassley, has initiated its own investigation into drug pricing, with ranking member Ron Wyden calling on drugmakers to come before the group to account for recent price rises.

The initial hearing comes at a time of renewed scrutiny on pricing from the US Congress, in the wake of mid-term elections which saw Democrats regain control of the lower chamber, the House of Representatives.

On that side of Congress, the House Oversight and Reform Committee has launched a separate investigation, led by Chairman and long-time industry critic Elijah Cummings.